Issues in recycling galvanized scrap

The quality of the steel used for most galvanizing (and tinplate) applications makes scrap derived from their production and use a premier solid charge material for steelmaking. In 1989 the AISI created a Task Force to define the issues and to recommend technologically and economically sound approaches to assure continued, unhindered recyclability of the growing volume of galvanized scrap. The AISI program addressed the treatment of full-sized industrial bales of scrap. The current, on-going MRI (US)--Argonne National Laboratory program is focused on ``loose`` scrap from industrial and post-consumer sources. Results from these programs, issues of scrap management from source to steel melting, the choices for handling zinc in iron and steelmaking and the benefits/costs for removal of zinc (and lead) from scrap prior to melting in BOF and foundry operations are reviewed in this paper

A Naturally Narrow Positive Parity Theta^+

We present a consistent color-flavor-spin-orbital wave function for a positive parity Theta^+ that naturally explains the observed narrowness of the state. The wave function is totally symmetric in its flavor-spin part and totally antisymmetric in its color-orbital part. If flavor-spin interactions dominate, this wave function renders the positive parity Theta^+ lighter than its negative parity counterpart. We consider decays of the Theta^+ and compute the overlap of this state with the kinematically allowed final states. Our results are numerically small. We note that dynamical correlations between quarks are not necessary to obtain narrow pentaquark widths.Comment: 10 pages, 1 figure, Revtex4, two-column format, version to be published in Phys. Rev. D, includes numerical estimates of decay width

Z^* Resonances: Phenomenology and Models

We explore the phenomenology of, and models for, the Z^* resonances, the lowest of which is now well established, and called the Theta. We provide an overview of three models which have been proposed to explain its existence and/or its small width, and point out other relevant predictions, and potential problems, for each. The relation to what is known about KN scattering, including possible resonance signals in other channels, is also discussed.Comment: 29 pages, uses RevTeX4; expanded version (published form

Heavy quarkonium: progress, puzzles, and opportunities

A golden age for heavy quarkonium physics dawned a decade ago, initiated by the confluence of exciting advances in quantum chromodynamics (QCD) and an explosion of related experimental activity. The early years of this period were chronicled in the Quarkonium Working Group (QWG) CERN Yellow Report (YR) in 2004, which presented a comprehensive review of the status of the field at that time and provided specific recommendations for further progress. However, the broad spectrum of subsequent breakthroughs, surprises, and continuing puzzles could only be partially anticipated. Since the release of the YR, the BESII program concluded only to give birth to BESIII; the $B$-factories and CLEO-c flourished; quarkonium production and polarization measurements at HERA and the Tevatron matured; and heavy-ion collisions at RHIC have opened a window on the deconfinement regime. All these experiments leave legacies of quality, precision, and unsolved mysteries for quarkonium physics, and therefore beg for continuing investigations. The plethora of newly-found quarkonium-like states unleashed a flood of theoretical investigations into new forms of matter such as quark-gluon hybrids, mesonic molecules, and tetraquarks. Measurements of the spectroscopy, decays, production, and in-medium behavior of c\bar{c}, b\bar{b}, and b\bar{c} bound states have been shown to validate some theoretical approaches to QCD and highlight lack of quantitative success for others. The intriguing details of quarkonium suppression in heavy-ion collisions that have emerged from RHIC have elevated the importance of separating hot- and cold-nuclear-matter effects in quark-gluon plasma studies. This review systematically addresses all these matters and concludes by prioritizing directions for ongoing and future efforts.Comment: 182 pages, 112 figures. Editors: N. Brambilla, S. Eidelman, B. K. Heltsley, R. Vogt. Section Coordinators: G. T. Bodwin, E. Eichten, A. D. Frawley, A. B. Meyer, R. E. Mitchell, V. Papadimitriou, P. Petreczky, A. A. Petrov, P. Robbe, A. Vair

Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

Background: In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To further assess a possible association and inform policy on future use of adjuvants, we conducted a multi-country study of narcolepsy and adjuvanted pH1N1 vaccines. Methods: We used electronic health databases to conduct a dynamic retrospective cohort study to assess narcolepsy incidence rates (IR) before and during pH1N1 virus circulation, and after pH1N1 vaccination campaigns in Canada, Denmark, Spain, Sweden, Taiwan, the Netherlands, and the United Kingdom. Using a case-control study design, we evaluated the risk of narcolepsy following AS03- and MF59-adjuvanted pH1N1 vaccines in Argentina, Canada, Spain, Switzerland, Taiwan, and the Netherlands. In the Netherlands, we also conducted a case-coverage study in children born between 2004 and 2009. Results: No changes in narcolepsy IRs were observed in any periods in single study sites except Sweden and Taiwan; in Taiwan incidence increased after wild-type pH1N1 virus circulation and in Sweden (a previously identified signaling country), incidence increased after the start of pH1N1 vaccination. No association was observed for Arepanrix-AS03 or Focetria-MF59 adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the case-control study nor for children born between 2004 and 2009 in the Netherlands case-coverage study for Pandemrix-AS03. Conclusions: Other than elevated narcolepsy IRs in the period after vaccination campaigns in Sweden, we did not find an association between AS03- or MF59-adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the sites studied, although power to evaluate the AS03-adjuvanted Pandemrix brand vaccine was limited in our study

Benefits of recycling galvanized steel scrap for recovery of high-quality steel and zinc metal

Argonne National Laboratory (ANL) and Metal Recovery Industries, Inc. (MRII), in cost-sharing collaboration, have developed an electrolytic process to separate and recover steel and zinc from galvanized steel scrap. This work has been supported by the US DOE. An assessment of available dezinc technology was begun in 1987 which (1) screened process concepts for separating and recovering zinc and steel from galvanized ferrous scrap, (2) selected electrochemical stripping in hot caustic as the most promising process, (3) evaluated the technical and economic feasibility of the selected process on the basis of fundamental electrochemical studies, (4) experimentally verified the technical and economic feasibility of the process in a phased evaluation from bench-scale controlled experiments through batch tests of actual scrap up to six ton lots, and (5) concluded that the process has technical and economic merit and requires larger- scale evaluation in a continuous mode as the final phase of process development. This work has attracted worldwide interest. Preliminary economic analysis indicates that the cost of the recovered ferrous scrap would be about $150/ton (at a base cost of$110/ton for galvanized scrap), including credit for the co-product zinc. Concentrations of zinc, lead, cadmium and other coating constituents on loose scrap are reduced by a minimum of 98%, with zinc, in particular, reduced to below 0.1%. Removal efficiencies on baled scrap with bulk densities between 60 and 245 pounds per cubic foot range from 80 to 90%. About 1000 tons of galvanized scrap bales have been treated in batch operation at MRII in Hamilton, Ontario. A pilot plant for continuous treatment of 40 ton/day of loose scrap is being built by MRII in East Chicago, Indiana, with operation starting in early 1992. 9 refs

A recycling process for dezincing steel scrap

In response to the several-fold increase in consumption of galvanized steel in the last decade and the problems associated with refurnacing larger quantities of galvanized steel scrap, a process is being developed to separate and recover the steel and zinc from galvanized ferrous scrap. The zinc is dissolved from the scrap in hot caustic using anodic assistance and is electrowon as dendritic powder. The process is effective for zinc, lead, aluminum, and cadmium removal on loose and baled scrap and on all types of galvanized steel. The process has been pilot tested for batch treatment of 1,000 tons of mostly baled scrap. A pilot plant to continuously treat loose scrap is under construction. Use of degalvanized steel scrap decreases raw materials and environmental compliance costs to steel- and iron-makers, may enable integrated steel producers to recycle furnace dusts to the sinter plant, and may enable EAF production of flat products without use of DRI or pig iron. Recycling the components of galvanized steel scrap saves primary energy, decreases zinc imports, and adds value to the scrap

In Vitro and In Vivo Antitumor Activity of a Novel Semisynthetic Derivative of Cucurbitacin B

Lung cancer is the most deadly type of cancer in humans, with non-small-cell lung cancer (NSCLC) being the most frequent and aggressive type of lung cancer showing high resistance to radiation and chemotherapy. Despite the outstanding progress made in anti-tumor therapy, discovering effective anti-tumor drugs is still a challenging task. Here we describe a new semisynthetic derivative of cucurbitacin B (DACE) as a potent inhibitor of NSCLC cell proliferation. DACE arrested the cell cycle of lung epithelial cells at the G2/M phase and induced cell apoptosis by interfering with EGFR activation and its downstream signaling, including AKT, ERK, and STAT3. Consistent with our in vitro studies, intraperitoneal application of DACE significantly suppressed the growth of mouse NSCLC that arises from type II alveolar pneumocytes due to constitutive expression of a human oncogenic c-RAF kinase (c-RAF-1-BxB) transgene in these cells. Taken together, these findings suggest that DACE is a promising lead compound for the development of an anti-lung-cancer drug